Dan Zenka, APR

Expert Opinion published on January 13, 2012 in Basic facts
Dan Zenka discusses why a man needs to understand his Gleason scores upon diagnosis of prostate cancer, as well as percentage of involvement in prostate gland. He addresses the importance of a patient having an in-depth discussion with his physicians to interpret the results.
Expert Opinion published on January 13, 2012 in Basic facts
Dan Zenka gives support and statistics that prostate cancer is not just an “old man’s disease.” He provides statistics on age groups that are newly diagnosed each year.
Expert Opinion published on January 13, 2012 in Symptoms
Dan Zenka discusses some of the symptoms of prostate cancer, as well as others that are not as common.
Expert Opinion published on January 13, 2012 in Diagnosis & Screening
Dan Zenka discusses the use of PSA (prostate-specific antigen) testing as a first-step diagnostic process for cancer. He addresses scoring and when it may be appropriate for a clinician to recommend a biopsy as the next step.
Expert Opinion published on January 13, 2012 in Diagnosis & Screening
Dan Zenka discusses the Gleason Score rating in a man’s biopsy pathology related to prostate cancer. He addresses how the assigned numbers indicate cell organization or disorganization and what this means to the patient.
Expert Opinion published on January 13, 2012 in Treatment
Dan Zenka discusses that there are more than 26 genotypes or varieties of prostate cancer. He addresses that there are some very slow growing, non life-threatening types, and some very aggressive types, and that a patient needs to look at all the treatment options that are available to them based upon testing and diagnosis.